Edgewise Therapeutics (NASDAQ: EWTX) net income
Edgewise Therapeutics reported a net loss of $167.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $133.8m. Earnings per share were −$1.63.
Edgewise Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$167.8m | — | — | −$1.63 |
| 2024 | −$133.8m | — | — | −$1.45 |
| 2023 | −$100.2m | — | — | −$1.57 |
| 2022 | −$67.6m | — | — | −$1.26 |
| 2021 | −$42.8m | — | — | −$1.14 |
| 2020 | −$17.1m | — | — | −$23.17 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Edgewise Therapeutics net income compared with its sector
By net income for its latest fiscal year, Edgewise Therapeutics ranks 395th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 393rd | Larimar Therapeutics | −$165.7m | — |
| 394th | Arrivent Biopharma | −$166.3m | — |
| 395th | Edgewise Therapeutics | −$167.8m | — |
| 396th | Cabaletta Bio | −$167.9m | — |
| 397th | ARS Pharmaceuticals | −$171.3m | −203.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Edgewise Therapeutics
- How much did Edgewise Therapeutics earn in fiscal 2025?
- Edgewise Therapeutics reported a net loss of $167.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $133.8m.
- What are the earnings per share of Edgewise Therapeutics?
- They were −$1.63 in fiscal 2025, compared with −$1.45 in fiscal 2024.
- Where does Edgewise Therapeutics rank in its sector by net income?
- It ranks 395th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Edgewise Therapeutics come from?
- From the annual report (Form 10-K) that Edgewise Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Edgewise Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Edgewise Therapeutics: the Edgewise Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.